1999 - Fellow of the American Association for the Advancement of Science (AAAS)
Member of the Association of American Physicians
Henry N. Ginsberg mainly focuses on Internal medicine, Endocrinology, Cholesterol, Diabetes mellitus and Lipoprotein. His Internal medicine study is mostly concerned with Triglyceride, Apolipoprotein B, High-density lipoprotein, Dyslipidemia and Disease. His Endocrinology study frequently draws connections between adjacent fields such as Statin.
Henry N. Ginsberg interconnects Niacin, Pharmacotherapy, Physiology and Blood plasma in the investigation of issues within Cholesterol. His study looks at the intersection of Diabetes mellitus and topics like Intensive care medicine with Residual risk, Fibrate and Guideline. His Lipoprotein research is multidisciplinary, relying on both Lipid peroxidation, Antioxidant, Vitamin E, Polyunsaturated fatty acid and Pioglitazone.
Internal medicine, Endocrinology, Apolipoprotein B, Cholesterol and Very low-density lipoprotein are his primary areas of study. His studies deal with areas such as Diabetes mellitus and Type 2 diabetes as well as Internal medicine. Henry N. Ginsberg works mostly in the field of Diabetes mellitus, limiting it down to topics relating to Statin and, in certain cases, Placebo and Alirocumab, as a part of the same area of interest.
Henry N. Ginsberg has included themes like Secretion, Endoplasmic reticulum, Microsomal triglyceride transfer protein and Low-density lipoprotein in his Apolipoprotein B study. His Cholesterol research integrates issues from Saturated fatty acid, Blood plasma and Cardiology. His Very low-density lipoprotein research incorporates themes from Catabolism, Steatosis and Apolipoprotein E.
His primary areas of investigation include Internal medicine, Endocrinology, Diabetes mellitus, Apolipoprotein B and Type 2 diabetes. His study in Lipoprotein, PCSK9, Alirocumab, Statin and Lipoprotein falls under the purview of Internal medicine. The Dyslipidemia research Henry N. Ginsberg does as part of his general Diabetes mellitus study is frequently linked to other disciplines of science, such as Gene expression, therefore creating a link between diverse domains of science.
His study in Dyslipidemia is interdisciplinary in nature, drawing from both Hypertriglyceridemia and Type 2 Diabetes Mellitus. His biological study spans a wide range of topics, including Chylomicron, Pancreatitis and Bioinformatics. His Type 2 diabetes research is multidisciplinary, incorporating elements of Acute coronary syndrome, Gastroenterology, Placebo, Fenofibrate and Hazard ratio.
Henry N. Ginsberg spends much of his time researching Internal medicine, Apolipoprotein B, Lipoprotein, Lipoprotein and PCSK9. The Internal medicine study combines topics in areas such as Diabetes mellitus and Endocrinology. His study in the field of Plasma levels, Metabolism, Anacetrapib and Cholesterylester transfer protein also crosses realms of Future studies.
His studies in Apolipoprotein B integrate themes in fields like Triglyceride and Atherosclerotic cardiovascular disease. His Lipoprotein research is multidisciplinary, incorporating perspectives in Clinical research, Secretion, Aortic valve disease, Stenosis and Disease. Henry N. Ginsberg usually deals with PCSK9 and limits it to topics linked to Alirocumab and Kexin.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the use and interpretation of assays for monitoring autophagy
Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham.
Effects of combination lipid therapy in type 2 diabetes mellitus.
Henry N. Ginsberg;Laura C. Lovato;Lawrence A. Leiter;Peter Linz.
The New England Journal of Medicine (2010)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society
Borge G. Nordestgaard;M. John Chapman;Steve E. Humphries;Henry N. Ginsberg.
European Heart Journal (2013)
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
DeWitt S. Goodman;Stephen B. Hulley;Luther T. Clark;C. E. Davis.
JAMA Internal Medicine (1988)
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus A Scientific Statement From the American Heart Association and the American Diabetes Association
John B. Buse;Henry N. Ginsberg;George L. Bakris;Nathaniel G. Clark.
Triglycerides and Cardiovascular Disease A Scientific Statement From the American Heart Association
Michael Miller;Neil J. Stone;Christie Ballantyne;Vera Bittner.
Lipoprotein(a) as a cardiovascular risk factor: current status
Børge G. Nordestgaard;M. John Chapman;Kausik Ray;Jan Borén.
European Heart Journal (2010)
Insulin resistance and cardiovascular disease
Henry N. Ginsberg.
Journal of Clinical Investigation (2000)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A Ference;Henry N Ginsberg;Ian T. Graham;Kausik K Ray.
European Heart Journal (2017)
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Emily Y. Chew;Walter T. Ambrosius;Matthew D. Davis;Ronald P. Danis.
The New England Journal of Medicine (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: